Migraine Clinical Trial
— MBRAIN-21Official title:
mBrain-21 : a Three-month Study on Context-awareness, Physiological Monitoring, and Machine Learning in Migraine and Cluster Headache
Verified date | February 2024 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study collects data from migraine and cluster headache patients during a three-month study. Contextual data (e.g. location or smartphone usage) and physiological variables will be used to assist machine learning algorithms in making predictions on activity, stress and sleep in patients with migraine or cluster headache.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 7, 2023 |
Est. primary completion date | September 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Adult participants between the age of 18 en 65 years. - Diagnosis of migraine without aura (ICHD-3 diagnosis 1.1) or migraine with aura (ICHD-3 diagnosis 1.2) or chronic migraine (ICHD-3 diagnosis 1.3) - Headache crystal clear days on minimum 5 days per month on average. - Onset of headache syndrome before the age of 50. - Attacks of migraine or cluster headache are clearly distinguishable from other types of headache disorders if present. - Participant complies with protocol to use smartphone applications on his or her own Android-based smartphone (minimum version 8.0) and to provide access to his or her smartphone dataplan. Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Belgium | University Hospital, Ghent: Department of Neurology | Ghent |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Feedback from participants | Feedback from participants on compliance, adherence, usability and user experience of study infrastructure | After 90 days | |
Primary | Accuracy (F1-scores) machine learning algorithms | Machine learning algorithms for stress detection, sleep detection, activity detection and headache attack detection | After 90 days | |
Secondary | Demographics | Demographic characteristics of participants | At the beginning of the study | |
Secondary | Headache phenotype characteristics | Headache phenotype characteristics | At the beginning of the study | |
Secondary | Migraine Specific Questionnaire v2.1 | Migraine Specific Questionnaire v2.1 | After 90 days | |
Secondary | MIDAS Migraine Disability Assessment | MIDAS Migraine Disability Assessment | After 90 days | |
Secondary | MOS Short-Form General Health Survey (SF-20) | MOS Short-Form General Health Survey (SF-20) | After 90 days | |
Secondary | Pittsburgh Sleep Quality index | Pittsburgh Sleep Quality index | After 90 days | |
Secondary | MUltilevel Assessment of Interoceptive Awareness v2 (MAIAv2) | MUltilevel Assessment of Interoceptive Awareness v2 (MAIAv2) | After 90 days | |
Secondary | Perceived Stress Scale (PSS-10) | Perceived Stress Scale (PSS-10) | After 90 days | |
Secondary | Connor Davidson Resilience Scale (CD-RISC 25) | Connor Davidson Resilience Scale (CD-RISC 25) | After 90 days | |
Secondary | Penn State Worry Questionnaire (PSWQ) | Penn State Worry Questionnaire (PSWQ) | After 90 days | |
Secondary | Perseverative Thinking Questionnaire (PTQ) | Perseverative Thinking Questionnaire (PTQ) | After 90 days | |
Secondary | Ruminative Response Scale (RRS) | Ruminative Response Scale (RRS) | After 90 days | |
Secondary | Basic Needs Scale | Basic Needs Scale | After 90 days | |
Secondary | Emotion Regulation Scale | Emotion Regulation Scale | After 90 days | |
Secondary | Neuroticism (subscale from BFI) | Neuroticism (subscale from BFI) | After 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |